Goldman initiated coverage on United Therapeutics with a new price target
$UTHR
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman initiated coverage of United Therapeutics with a rating of Sell and set a new price target of $230.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $405.00 | Overweight | Cantor Fitzgerald |
| 4/25/2025 | Overweight → Equal Weight | Wells Fargo | |
| 4/21/2025 | $314.00 | Underperform → Neutral | BofA Securities |
| 7/11/2024 | $310.00 → $321.00 | Overweight → Equal-Weight | Morgan Stanley |
| 2/12/2024 | $213.00 → $215.00 | Sell → Neutral | Goldman |
| 2/5/2024 | $330.00 | Outperform | Leerink Partners |
| 12/8/2023 | $309.00 | Overweight | Wells Fargo |
| 12/6/2022 | $320.00 | Buy | UBS |
Cantor Fitzgerald initiated coverage of United Therapeutics with a rating of Overweight and set a new price target of $405.00
Wells Fargo downgraded United Therapeutics from Overweight to Equal Weight
BofA Securities upgraded United Therapeutics from Underperform to Neutral and set a new price target of $314.00